【摘要】 目的观察抗人VEGF单抗E11对小鼠肉瘤S180生长的影响。方法BALB/c小鼠45只,接种小鼠肉瘤细胞株S180,随机均分为5组。其中3组于接种后1～4、7～11天,分别通过腹腔或瘤周皮下注射抗人VEGF单抗E11100μg、200μg。另以生理盐水及5-Fu注射作阴性及阳性对照组。接种后第14天处死小鼠并称取瘤重,计算抑瘤率,并做组织病理学检查。结果抗人VEGF单抗皮下及腹腔给药均可抑制S180肉瘤的生长,且抗人VEGF单抗200μg/d组抑瘤率均高于5-Fu组;皮下给药组抑瘤率最高,达67.2%。结论不同剂量、不同给药途径的抗人VEGF单抗对小鼠肉瘤S180的生长均有明显抑制作用,说明抗人VEGF单抗可通过阻断VEGF的作用,抑制肿瘤血管生成,从而达到抑制肿瘤生长的目的。提示抗人VEGF单抗具有可能的临床应用前景。更多还原

【Abstract】 Objective The purpose of this study was to apply the anti-VEGF MAb(E11),which was generated against a synthetic peptide from the NH 2 of the human VEGF(residues1-26),to against VEGF in the mice fibrosarcoma S180and observe the inhibition effect of tumor growth.Methods The mice fibrosarcoma cell lines S180was injected s.c.into BALB/c mice,and then these mice were randomized into three groups.The anti-human VEGF MAb was administered i.p.or s.c.with100μg or200μg each injection on days1-4,7-11.Normal saline or5-Fu was administrated i.p.separately as control groups.Mice were sacrificed on14th day.The tumor weight was determined and the inhibition rate was calculated.Results The growth of S180fibrosacoma in MAb-treated group was dramatically inhibited,especially in MAb adminis-trated s.c.group.The tumor growth inhibition rate in mice treated s.c.with MAb reached67.2%.Conclusion The anti-human VEGF MAb had a significant inhibitory effect on growth of mouse fibrosarcoma by blocking the action of VEGF,without marked side effects.The results indicated that VEGF played an important role as a tumor angiogenesis factor,and the anti-human VEGF MAb had a potential application for clinical treatment of malignant tumors.更多还原